Login to Your Account



ISA Moving HPV Vaccine into Phase II with $10.5M Round

By Cormac Sheridan
Staff Writer

Wednesday, January 9, 2013
ISA Pharmaceuticals BV raised €8 million (US$10.5 million) in an internal financing round to fund a Phase II trial of its therapeutic vaccine for cervical cancer, ISA-HPV.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription